#$RGNX Mizuho initiates with Outperform, PT $22 vs current ~$7.60 — roughly 189% implied upside.
- RGX-202 (Duchenne muscular dystrophy) U.S. filing expected Q1 2027
- Phase 3 sura-vec data in wet AMD due this quarter
- Two near-term catalysts driving the bull case
- RGX-202 (Duchenne muscular dystrophy) U.S. filing expected Q1 2027
- Phase 3 sura-vec data in wet AMD due this quarter
- Two near-term catalysts driving the bull case
October 5, 2026 at 9:38 AM
#$RGNX Mizuho initiates with Outperform, PT $22 vs current ~$7.60 — roughly 189% implied upside.
- RGX-202 (Duchenne muscular dystrophy) U.S. filing expected Q1 2027
- Phase 3 sura-vec data in wet AMD due this quarter
- Two near-term catalysts driving the bull case
- RGX-202 (Duchenne muscular dystrophy) U.S. filing expected Q1 2027
- Phase 3 sura-vec data in wet AMD due this quarter
- Two near-term catalysts driving the bull case
BofA calls the clinical hold on #$RGNX RGX-121 (from silent spine MRI issues in 5 patients) disappointing, undoing July progress. No near-term resubmission expected; they already valued it little. Next catalyst: starting the ’202 BLA filing this quarter. Still Buy rated with $15 target.
FDA places clinical hold on #$RGNX RGX-121 for Hunter Syndrome after asymptomatic spine MRI findings in 5 patients. Patients remain well; no near-term BLA resubmission. notreload.xyz/xy/fda-place...
FDA Places Clinical Hold on REGENXBIO’s RGX-121 Gene Therapy
FDA places clinical hold on REGENXBIO’s RGX-121 for Hunter Syndrome after asymptomatic spine MRI findings in 5 patients. Patients remain well; no near-term BLA resubmission.
notreload.xyz
August 24, 2026 at 4:34 PM
BofA calls the clinical hold on #$RGNX RGX-121 (from silent spine MRI issues in 5 patients) disappointing, undoing July progress. No near-term resubmission expected; they already valued it little. Next catalyst: starting the ’202 BLA filing this quarter. Still Buy rated with $15 target.
REGENXBIO publicó un comunicado de prensa y realizó su llamada en conferencia sobre los resultados del segundo trimestre
Y compartió las actualizaciones clave para RGX-202, su terapia génica investigacional para la DMD.
#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #REGENXBIO
Y compartió las actualizaciones clave para RGX-202, su terapia génica investigacional para la DMD.
#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #REGENXBIO
August 7, 2026 at 2:52 PM
REGENXBIO publicó un comunicado de prensa y realizó su llamada en conferencia sobre los resultados del segundo trimestre
Y compartió las actualizaciones clave para RGX-202, su terapia génica investigacional para la DMD.
#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #REGENXBIO
Y compartió las actualizaciones clave para RGX-202, su terapia génica investigacional para la DMD.
#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #REGENXBIO
The RGX-202 compound is currently also tested in clinical trials, so far with promising results, though it is early days so we can only be cautiously optimistic.
Full disclosure: I consult for Regenxbio, but was not involved in the set up or analysis of this study
Full disclosure: I consult for Regenxbio, but was not involved in the set up or analysis of this study
May 6, 2026 at 8:13 AM
The RGX-202 compound is currently also tested in clinical trials, so far with promising results, though it is early days so we can only be cautiously optimistic.
Full disclosure: I consult for Regenxbio, but was not involved in the set up or analysis of this study
Full disclosure: I consult for Regenxbio, but was not involved in the set up or analysis of this study
Authors work for Regenxbio and here report on a very comprehensive test in the mdx mouse model, for the RGX-202 compound, which uses AAV8 and a micro-dystrophin that is slightly longer than the one others are using, with a complete c-terminal domain.
May 6, 2026 at 7:42 AM
Authors work for Regenxbio and here report on a very comprehensive test in the mdx mouse model, for the RGX-202 compound, which uses AAV8 and a micro-dystrophin that is slightly longer than the one others are using, with a complete c-terminal domain.
#$RGNX reported Q1 2026 revenue of just $6.4M — missing Wall Street estimates by $19.4M — sending shares down 18%. Strong pivotal Duchenne gene therapy data for RGX-202 offers major long-term upside. notreload.xyz/xy/regenxbio...
REGENXBIO Misses Q1 Revenue by $19M, Shares Fall
Regenxbio’s DMD gene therapy showed strong results, boosting muscle protein and safety, moving closer to FDA approval.
notreload.xyz
May 14, 2026 at 1:24 PM
#$RGNX reported Q1 2026 revenue of just $6.4M — missing Wall Street estimates by $19.4M — sending shares down 18%. Strong pivotal Duchenne gene therapy data for RGX-202 offers major long-term upside. notreload.xyz/xy/regenxbio...
$RGNX +8% [REGENXBIO stock rises after positive 18-month trial data for RGX-202, its one-time gene therapy treating Duchenne muscular dystrophy in boys.] notreload.xyz/regenxbio-sh...
REGENXBIO Shares Rise on Positive Duchenne Therapy Results
REGENXBIO stock rises 8% after positive 18-month trial data for RGX-202, its one-time gene therapy treating Duchenne muscular dystrophy in boys.
notreload.xyz
January 12, 2026 at 12:28 PM
$RGNX +8% [REGENXBIO stock rises after positive 18-month trial data for RGX-202, its one-time gene therapy treating Duchenne muscular dystrophy in boys.] notreload.xyz/regenxbio-sh...
$RGNX -2.5% [BofA highlights that Regenxbio's immune suppression may enhance RGX-202's safety and expects no changes after a competitor's safety issue, maintaining a Buy rating and $22 target.]
June 16, 2025 at 5:17 PM
$RGNX -2.5% [BofA highlights that Regenxbio's immune suppression may enhance RGX-202's safety and expects no changes after a competitor's safety issue, maintaining a Buy rating and $22 target.]
REGENXBIO Announces Completion of RGX-202 Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
#dmd #duchenne #regenxbio #genetherapy #clinicaltrials #rgx202
👉 Read More: DMDWarrioR.com
#dmd #duchenne #regenxbio #genetherapy #clinicaltrials #rgx202
👉 Read More: DMDWarrioR.com
October 30, 2025 at 1:06 PM
REGENXBIO Announces Completion of RGX-202 Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program
#dmd #duchenne #regenxbio #genetherapy #clinicaltrials #rgx202
👉 Read More: DMDWarrioR.com
#dmd #duchenne #regenxbio #genetherapy #clinicaltrials #rgx202
👉 Read More: DMDWarrioR.com
RGX-202 microdystrophin expression results in ambulatory patients aged 8+ are the highest reported microdystrophin levels across approved or investigational gene therapies.
Source: regenxbio.gcs-web.com/news-release...
#dmd #regenxbio #RGX202 #AFFINITYDUCHENNE #AAV8
Source: regenxbio.gcs-web.com/news-release...
#dmd #regenxbio #RGX202 #AFFINITYDUCHENNE #AAV8
November 18, 2024 at 5:15 PM
RGX-202 microdystrophin expression results in ambulatory patients aged 8+ are the highest reported microdystrophin levels across approved or investigational gene therapies.
Source: regenxbio.gcs-web.com/news-release...
#dmd #regenxbio #RGX202 #AFFINITYDUCHENNE #AAV8
Source: regenxbio.gcs-web.com/news-release...
#dmd #regenxbio #RGX202 #AFFINITYDUCHENNE #AAV8
The science: Duchenne comes from mutations in the gene for dystrophin, a protein that keeps muscle fibers from tearing apart as they contract. Without it, muscle slowly breaks down. RGX-202 delivers a working, shortened copy of that gene into muscle so the body can make it again.
June 8, 2026 at 4:56 PM
The science: Duchenne comes from mutations in the gene for dystrophin, a protein that keeps muscle fibers from tearing apart as they contract. Without it, muscle slowly breaks down. RGX-202 delivers a working, shortened copy of that gene into muscle so the body can make it again.
Duchenne muscular dystrophy already has one approved gene therapy. Last month a second one — Regenxbio's RGX-202 — hit its main trial goal and is heading to the FDA, with the claim that it's safer and works better. Here's what that actually means for families. 🧵
June 8, 2026 at 4:56 PM
Duchenne muscular dystrophy already has one approved gene therapy. Last month a second one — Regenxbio's RGX-202 — hit its main trial goal and is heading to the FDA, with the claim that it's safer and works better. Here's what that actually means for families. 🧵
#Regenxbio is pitching at #FDA approval next year for its #Duchennemusculardystrophy (DMD) #genetherapy RGX-202, after reporting topline results from a pivotal phase 3 trial.
buff.ly/GCZibrn
buff.ly/GCZibrn
May 14, 2026 at 2:00 PM
#Regenxbio is pitching at #FDA approval next year for its #Duchennemusculardystrophy (DMD) #genetherapy RGX-202, after reporting topline results from a pivotal phase 3 trial.
buff.ly/GCZibrn
buff.ly/GCZibrn
Feed: "Parent Project Muscular Dystrophy"
Published on Thursday, May 14, 2026
Published on Thursday, May 14, 2026
REGENXBIO Shares Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
REGENXBIO Inc. has announced positive topline and interim functional data from the pivotal Phase III portion of the Phase I/II/III AFFINITY DUCHENNE® trial of RGX-202, an investigational gene therapy being developed for individuals with Duchenne...
www.parentprojectmd.org
May 15, 2026 at 12:07 AM
Feed: "Parent Project Muscular Dystrophy"
Published on Thursday, May 14, 2026
Published on Thursday, May 14, 2026
Feed: "Parent Project Muscular Dystrophy"
Published on Wednesday, March 11, 2026
Published on Wednesday, March 11, 2026
REGENXBIO Shares Positive Interim Data from Phase I/II AFFINITY DUCHENNE Trial of RGX-202
REGENXBIO has announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, an investigational gene therapy being developed for individuals with Duchenne muscular dystrophy. RGX-202 is designed to deliver microdystrophin via...
www.parentprojectmd.org
March 12, 2026 at 5:51 PM
Feed: "Parent Project Muscular Dystrophy"
Published on Wednesday, March 11, 2026
Published on Wednesday, March 11, 2026
Feed: "Clinical Trials Arena"
By: sdebbarma on Friday, October 31, 2025
By: sdebbarma on Friday, October 31, 2025
REGENXBIO concludes subject enrolment in trial of RGX-202
REGENXBIO has concluded enrolment of subjects in the AFFINITY DUCHENNE clinical study evaluating its RGX-202 gene therapy candidate for Duchenne muscular dystrophy.
www.clinicaltrialsarena.com
November 1, 2025 at 7:00 AM
Feed: "Clinical Trials Arena"
By: sdebbarma on Friday, October 31, 2025
By: sdebbarma on Friday, October 31, 2025
Feed: "Parent Project Muscular Dystrophy"
Published on Thursday, June 5, 2025
Published on Thursday, June 5, 2025
REGENXBIO Shares Positive Functional Data from Phase I/II AFFINITY DUCHENNE Trial of RGX-202
Today, REGENXBIO announced new data from its ongoing Phase I/II AFFINITY DUCHENNE® trial of RGX-202, an investigational gene therapy being developed for individuals with Duchenne muscular dystrophy. RGX-202 is designed to deliver microdystrophin via AAV8...
www.parentprojectmd.org
June 7, 2025 at 6:51 AM
Feed: "Parent Project Muscular Dystrophy"
Published on Thursday, June 5, 2025
Published on Thursday, June 5, 2025
🔗Lee el artículo completo aquí: https://theakarifoundation-pr.org/regenxbio-completa-dosificacion-en-el-estudio-confirmatorio-de-la-terapia-rgx-202-marcando-la-finalizacion-del-programa-de-desarrollo-registracional-y-respaldando-el-envio-previsto-de-la-solicitud-de/
#TheAkariFoundation #REGENXBIO
#TheAkariFoundation #REGENXBIO
June 24, 2026 at 9:37 PM
📣The Akari Foundation los invita al Webinar “Panorama general de la terapia génica y del fármaco en investigación RGX-202 para la distrofia muscular de Duchenne”.
🗓MARTES 30 de JUNIO, a las 6:30 pm, vía Zoom.
🔗Regístrate aquí: https://us06web.zoom.us/webinar/register/WN_x79Ak6ttTkKpwxIxXxM09A
🗓MARTES 30 de JUNIO, a las 6:30 pm, vía Zoom.
🔗Regístrate aquí: https://us06web.zoom.us/webinar/register/WN_x79Ak6ttTkKpwxIxXxM09A
June 19, 2026 at 3:55 PM
📣The Akari Foundation los invita al Webinar “Panorama general de la terapia génica y del fármaco en investigación RGX-202 para la distrofia muscular de Duchenne”.
🗓MARTES 30 de JUNIO, a las 6:30 pm, vía Zoom.
🔗Regístrate aquí: https://us06web.zoom.us/webinar/register/WN_x79Ak6ttTkKpwxIxXxM09A
🗓MARTES 30 de JUNIO, a las 6:30 pm, vía Zoom.
🔗Regístrate aquí: https://us06web.zoom.us/webinar/register/WN_x79Ak6ttTkKpwxIxXxM09A
REGENXBIO se complace compartir las actualizaciones sobre el ensayo de Fase I/II AFFINITY DUCHENNE® de RGX-202*, la terapia génica en investigación de REGENXBIO para la distrofia muscular de Duchenne.
#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #REGENXBIO #AFFINITYDUCHENNE
#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #REGENXBIO #AFFINITYDUCHENNE
March 13, 2026 at 4:12 PM
REGENXBIO se complace compartir las actualizaciones sobre el ensayo de Fase I/II AFFINITY DUCHENNE® de RGX-202*, la terapia génica en investigación de REGENXBIO para la distrofia muscular de Duchenne.
#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #REGENXBIO #AFFINITYDUCHENNE
#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #REGENXBIO #AFFINITYDUCHENNE
📢REGENXBIO nos comparte una actualización sobre la terapia en investigación RGX-202 de REGENXBIO para el tratamiento de la distrofia muscular de Duchenne (Duchenne).
November 1, 2025 at 4:00 PM
📢REGENXBIO nos comparte una actualización sobre la terapia en investigación RGX-202 de REGENXBIO para el tratamiento de la distrofia muscular de Duchenne (Duchenne).